Tumor regression in mice by delivery of Bcl-2 small interfering RNA with pegylated cationic liposomes.
The pharmacokinetics and antitumor activity of pegylated small interfering RNA (siRNA)/cationic liposome complexes were studied after systemic administration to mice. We designed pegylated-lipid carriers for achieving increased plasma concentrations of RNA and hence improved accumulation of RNA in tumors by the enhanced permeability and retention effect. We compared the pharmacokinetics of siRNA complexed with liposomes incorporating pegylated lipids with longer (C-17 or C-18), shorter (C-12 to C-16), or unsaturated (C-18:1) acyl chains. When longer acyl chains were used, the plasma concentrations of siRNA obtained were dramatically higher than when shorter or unsaturated chains were used. This may be explained by the higher gel-to-liquid-crystalline phase-transition temperature (Tc) of lipids with longer acyl chains, which may form more rigid liposomes with reduced uptake by the liver. We tested a siRNA that is sequence specific for the antiapoptotic bcl-2 mRNA complexed with a pegylated liposome incorporating a C-18 lipid (PEG-LIC) by i.v. administration in a mouse model of human prostate cancer. Three-fold higher accumulation of RNA in the tumors was achieved when PEG-LIC rather than nonpegylated liposomes was used, and sequence-specific antitumor activity was observed. Our siRNA/PEG-LIC complex showed no side effects on repeated administration and the strength of its antitumor activity may be attributed to its high uptake by the tumors. Pegylation of liposomes improved the plasma retention, uptake by s.c. tumors, and antitumor activity of the encapsulated siRNA. PEG-LIC is a promising candidate for siRNA cancer therapy.
Sonoke
Satoru
S
Discovery Research Laboratories, Nippon Shinyaku Co Ltd, Tsukuba, Japan. s.sonoke@po.nippon-shinyaku.co.jp
Ueda
Toshihiro
T
Fujiwara
Kae
K
Sato
Yohei
Y
Takagaki
Kazuchika
K
Hirabayashi
Kazuko
K
Ohgi
Tadaaki
T
Yano
Junichi
J
D000818:Animals; D001483:Base Sequence; D002412:Cations; D045744:Cell Line, Tumor; D020868:Gene Silencing; D006801:Humans; D008081:Liposomes; D051379:Mice; D008807:Mice, Inbred BALB C; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000235:genetics*; D034741:RNA, Small Interfering / Q000008:administration & dosage* / Q000493:pharmacokinetics
D002412:Cations; D008081:Liposomes; D019253:Proto-Oncogene Proteins c-bcl-2; D034741:RNA, Small Interfering